News for '-zydus'

HC allows Zydus to sell generic version of cancer drug nivolumab

HC allows Zydus to sell generic version of cancer drug nivolumab

Rediff.com13 Jan 2026

Delhi High Court has cleared the way for Zydus Lifesciences to proceed with the sale of its version of the cancer drug nivolumab in India. nivolumab is used to treat several types of cancer by activating the body's immune system to target carcinogenic cells.

Zydus PAT rises 38% on strong India, US growth

Zydus PAT rises 38% on strong India, US growth

Rediff.com7 Nov 2025

Ahmedabad-headquartered Zydus Lifesciences posted a 17 per cent year-on-year (Y-o-Y) rise in revenue from operations to Rs 6,123 crore, while the net profit increased by 38 per cent to Rs 1,258.6 crore aided by consistent performance in the US and India formulations businesses.

AI is fast becoming central to how drugs will be discovered

AI is fast becoming central to how drugs will be discovered

Rediff.com25 Feb 2026

Artificial intelligence (AI) is no longer a side conversation for Indian pharma. It is fast becoming central to how drugs will be discovered, made, and supplied. Along with that shift comes a sharper focus on innovation, on the one hand, and quality and trust, on the other.

Domestic sales a booster dose for pharma revenues

Domestic sales a booster dose for pharma revenues

Rediff.com19 Jan 2026

Buoyant domestic sales are expected to lift revenues for pharma companies by 8-11 per cent in Q3FY26, even as declining generic Revlimid (cancer drug) sales in the US remain a key drag. Most brokerages forecast a modest 2-4 per cent growth in profit after tax (PAT) for the quarter. Hospitals and diagnostics companies, meanwhile, are likely to post much stronger numbers, with revenues seen growing 20-22 per cent year-on-year (Y-o-Y).

Indian pharma to get stronger dose of EU mkt access

Indian pharma to get stronger dose of EU mkt access

Rediff.com5 Feb 2026

The European Union's (EU's) offer to slash tariffs on 97.5 per cent of Indian chemical exports to zero is set to give India's pharmaceutical and medical device firms preferential access to the European markets.

Zydus gets China nod for kidney disease drug

Zydus gets China nod for kidney disease drug

Rediff.com24 Apr 2024

Ahmedabad-based Zydus Lifesciences said on Tuesday that a new drug application for its oral drug Desidustat used in treating anaemia in chronic kidney disease (CKD) patients had been accepted by the National Medical Products Administration of China (NMPA). In 2020, CMS International Development and Management Ltd, a wholly-owned subsidiary of China Medical System Holdings Ltd obtained an exclusive license for the product from Zydus. CKD involves a gradual loss of functioning of kidneys and eventually leads to kidney failure.

Trump's 100% tariff on pharma unlikely to hurt domestic industry: Experts

Trump's 100% tariff on pharma unlikely to hurt domestic industry: Experts

Rediff.com26 Sep 2025

Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.

Pharma stocks slide as US headwinds hurt

Pharma stocks slide as US headwinds hurt

Rediff.com16 Sep 2025

Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.

'Medicines are just one part of the solution'

'Medicines are just one part of the solution'

Rediff.com21 May 2025

'We are looking at what kind of products, diagnostics or other solutions we can offer to become a well-rounded player in a particular disease area globally.'

Day after ED arrest, Gujarat Samachar owner gets temporary bail

Day after ED arrest, Gujarat Samachar owner gets temporary bail

Rediff.com17 May 2025

The Enforcement Directorate on Friday detained Bahubali Shah, one of the owners of the leading Gujarati newspaper Gujarat Samachar, following a raid on their premises in Ahmedabad, sources said.

Why Zydus is likely to continue with its outperformance

Why Zydus is likely to continue with its outperformance

Rediff.com31 Mar 2023

Even as most of its large-cap pharmaceutical peers have struggled to stay above water on the returns front, Zydus Lifesciences has been one of the big outperformers within the sector over the past year with a return of over 30 per cent. The gains have come on the back of multiple triggers such as the scaling up of new product launches in the US market, clearance for its Moraiya (Gujarat) facility and steady performance in the domestic market. Though it has been the top pharma gainer in the 2022-23 financial year (FY23), brokerages continue to maintain their 'buy' stance, given the strong visibility in the US market.

Zydus Cadila starts supply of COVID-19 vaccine to govt

Zydus Cadila starts supply of COVID-19 vaccine to govt

Rediff.com2 Feb 2022

ZyCoV-D is a three-dose vaccine administered intradermally.

Indian Pharma Gets Relief from Trump's Tariffs

Indian Pharma Gets Relief from Trump's Tariffs

Rediff.com4 Apr 2025

Indian drugmakers supply 47 per cent of the generic medicine requirements in the US, and tariffs would have increased prices in the US domestic market for patients, who are already dealing with drug shortages.

Lower input costs may aid pharma firms' Q2 margins

Lower input costs may aid pharma firms' Q2 margins

Rediff.com21 Oct 2024

Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points. Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y). Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so.

This will Likely Shape the Future of Pharma Inc

This will Likely Shape the Future of Pharma Inc

Rediff.com8 Mar 2025

Indian pharmaceutical companies may have units abroad as part of "distributed manufacturing" across various locations, according to industry veterans. This may come about over the next five to 10 years.

Zydus's India-made Covid vaccine gets emergency use approval

Zydus's India-made Covid vaccine gets emergency use approval

Rediff.com20 Aug 2021

This is the world's first DNA-based vaccine against the coronavirus, and this three-dose vaccine when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from the disease as well as viral clearance

Zydus Cadila seeks nod for its COVID vaccine for 12 years, above

Zydus Cadila seeks nod for its COVID vaccine for 12 years, above

Rediff.com1 Jul 2021

Drug firm Zydus Cadila on Thursday said it has applied for emergency use authorisation (EUA) with the Indian drug regulator for its three-dose COVID-19 vaccine ZyCoV-D, and plans to manufacture 10-12 crore doses annually.

7 states to get Zydus Cadila's Covid vax ZyCoV-D

7 states to get Zydus Cadila's Covid vax ZyCoV-D

Rediff.com2 Dec 2021

The seven states are Bihar, Jharkhand, Maharashtra, Punjab, Tamil Nadu, Uttar Pradesh and West Bengal.

Zydus Cadila to begin vaccine trials for kids above 5 yrs soon

Zydus Cadila to begin vaccine trials for kids above 5 yrs soon

Rediff.com19 Jul 2021

So far, no other vaccine has been approved globally for children below 12 years. Sohini Das reports.

No remarks without expertise: HC orders influencer to remove Complan videos

No remarks without expertise: HC orders influencer to remove Complan videos

Rediff.com27 Sep 2024

The court said a social media influencer is expected not to try to play the role of a professional without any backing to substantiate what is being shared by them.

Zydus Cadila reduces price of its vax for those above 12 yrs

Zydus Cadila reduces price of its vax for those above 12 yrs

Rediff.com31 Oct 2021

Zydus Cadila has agreed to bring down the price of its COVID-19 vaccine to Rs 265 a dose following persistent negotiations by the government but a final deal is yet to be reached, sources said on Sunday.

Zydus infringed Takeda's patent, rules US court

Zydus infringed Takeda's patent, rules US court

Rediff.com20 Jun 2013

Takeda had filed a case of patent infringement in response to Zydus' abbreviated new drug application.

Zydus Cadila, Mayne form JV

Zydus Cadila, Mayne form JV

Rediff.com19 May 2005

Pharma major Zydus Cadila on Thursday entered into an agreement with Mayne Pharma of Australia to set up a 50:50 joint venture company

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Rediff.com11 Jun 2024

The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.

Zydus may set up US facility

Zydus may set up US facility

Rediff.com21 Jan 2005

Zydus buys Spain's Laboratorios Combix

Zydus buys Spain's Laboratorios Combix

Rediff.com31 May 2008

Ahmedabad-based Zydus Cadila, India's fourth largest pharma company with a turnover of Rs 2,300 crore, has acquired 100 per cent stake in Laboratorios Combix of Spain, marking its entry into Europe's fifth largest pharmaceutical market. The company bought the Spanish firm for an undisclosed amount.

Zydus Cadila sets up US arm

Zydus Cadila sets up US arm

Rediff.com15 Jan 2004

Ahmedabad-based Zydus Cadila has made a foray into the US generic formulation segment by setting up a subsidiary Zydus Pharmaceuticals USA, Inc.

Zydus unveils 43 generics in France

Zydus unveils 43 generics in France

Rediff.com17 Sep 2004

Zydus Cadila proposes Rs 1,900 for 3 jabs of DNA-based vaccine

Zydus Cadila proposes Rs 1,900 for 3 jabs of DNA-based vaccine

Rediff.com3 Oct 2021

With talks underway between the central government and Zydus Cadila over the pricing of the COVID-19 vaccine ZyCov-D, the pharma company is learnt to have proposed a price of Rs 1,900 for its three-dose jab that can be given to those above 12 years of age.

Coming! Changes In Mid Caps, Large Caps

Coming! Changes In Mid Caps, Large Caps

Rediff.com19 Jun 2024

Midcap stocks Hero MotoCorp, Zydus Lifesciences, JSW Energy, NHPC, Bharat Heavy Electricals, Bosch, and Samvardhana Motherson are expected to earn upgrades.

Pharma cos okay with QR codes to combat counterfeit drugs

Pharma cos okay with QR codes to combat counterfeit drugs

Rediff.com19 Jul 2024

As the Drugs Controller General of India (DCGI) is set to crack down on companies to ensure compliance with printing QR codes on top-selling brands to curb counterfeiting, top pharma companies say they welcome the regulator's mandate and that they are on track. They also view it as a positive step to ensure patient safety. Sheetal Arora, CEO of Mankind Pharmaceuticals, which has already adopted QR codes in 20 of their products, stated: "We strongly advocate for mandatory implementation of barcodes and QR codes on medicines as this initiative will not only protect patients but also strengthen the integrity of our healthcare system by reducing circulation of counterfeit drugs."

Zydus' Virafin gets emergency use approval for treating moderate COVID-19 cases

Zydus' Virafin gets emergency use approval for treating moderate COVID-19 cases

Rediff.com23 Apr 2021

This government's approval for use of the antiviral drug comes at a time when India's daily COVID tally is crossing the 3-lakh mark.

Zydus Cadila to sell Atenolol in US

Zydus Cadila to sell Atenolol in US

Rediff.com1 Feb 2005

Cadila Healthcare Ltd has announced that Zydus Cadila has received its very first approval from USFDA to market Atenolol, an anti-hypertensive drug, in the US market.

Zydus, Tyco in pact to sell drugs in US

Zydus, Tyco in pact to sell drugs in US

Rediff.com9 Mar 2005

Zydus Pharmaceuticals Inc, the US arm of Zydus Cadila has entered into a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a business unit of Tyco Healthcare to market generic products in the US.

Hero Motocorp, JSW energy among 7 midcap stocks likely to get largecap tag

Hero Motocorp, JSW energy among 7 midcap stocks likely to get largecap tag

Rediff.com14 Jun 2024

Mutual funds' largecap investment universe is expected to see seven changes in the upcoming stock reclassification exercise by the Association of Mutual Funds in India (Amfi). According to a report by IIFL Securities, Hero MotoCorp, Zydus Lifesciences, JSW Energy, NHPC, Bharat Heavy Electricals, Bosch and Samvardhana Motherson are expected to earn upgrades in the revised list of largecap, midcap and smallcap stocks set to be released in the first week of July. Amfi revises the list at the start of January and July every year based on the previous six-month performance of the stock.

India just shy of top-weight China in MSCI EM after rejig

India just shy of top-weight China in MSCI EM after rejig

Rediff.com14 Aug 2024

The Indian equity markets will soon account for over a fifth of a key emerging market (EM) benchmark tracked by funds with assets exceeding $500 billion. This development is expected to funnel as much as $3 billion into the domestic markets. Following the latest review undertaken by global index provider MSCI, India's weighting in the MSCI EM index will surpass 20 per cent for the first time, narrowing its gap with the current top-weighted China to fewer than 400 basis points.

Cadila, Zydus to buy out Heinz India for Rs 4595 cr

Cadila, Zydus to buy out Heinz India for Rs 4595 cr

Rediff.com24 Oct 2018

Acquisition of popular brands such as Complan, Glucon D, Nycil and Sampriti Ghee from Heinz India would be a part of the deal, Cadila Healthcare said in a filing to BSE.